Lv11
48 积分 2025-05-09 加入
Pharmacokinetics, Safety, and Tolerability of GS‐1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants
6天前
已完结
Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023
6天前
已完结
A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson’s disease
20天前
已完结
Safety, Tolerability, Pharmacokinetics, and Target Engagement of Single and Multiple Ascending Doses of Intravenous AZD4144, a Small Molecule NLRP3 Inhibitor for Treatment of AKI
1个月前
已关闭
REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer
1个月前
已完结
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
1个月前
已完结
Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases
1个月前
已完结
Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor
1个月前
已完结
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
1个月前
已完结
Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement
1个月前
已完结
皖公网安备34019202002308
